Drug therapy in Behçet's disease

Behçet's disease is one of the most difficult forms of uveitis to treat. Variety in disease presentation and severity, as well as regional differences in standard of care, demand a tailor-made approach. Anterior segment inflammation generally responds to topical corticosteroids. However, the onset of posterior segment inflammation usually requires the advancement of treatment to periocular injections and/or oral administration of corticosteroids. Cyclosporin, either alone or in combination with corticosteroids, is considered in refractory patients. Other immunosuppressive drugs, such as azathioprine and chlorambucil, may be considered in difficult cases. Finally, preliminary results suggest efficacy with the immunomodulatory agent interferon alfa, although further clinical trials are necessary to evaluate safety and efficacy.

[1]  O. Ozcebe,et al.  Behçet's disease. , 2019, The New England journal of medicine.

[2]  S. Kotake,et al.  Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy. , 1999, Ophthalmology.

[3]  J. Mizuguchi,et al.  Kinetics of intraocular cytokines in the suppression of experimental autoimmune uveoretinitis by type I IFN. , 1998, International immunology.

[4]  E. Matteson,et al.  Interferon-α treatment of Behçet's disease , 1998 .

[5]  C. Zouboulis,et al.  Treatment of Adamantiades-Behçet disease with systemic interferon alfa. , 1998, Archives of dermatology.

[6]  M. Zierhut,et al.  Treatment of ocular symptoms of Behçet’s disease with interferon α2a: a pilot study , 1998 .

[7]  Georgiou,et al.  Efficacy and safety of systemic recombinant interferon‐alpha in Behcet's disease , 1998, Journal of internal medicine.

[8]  R. Priori,et al.  INTERFERON A FOR OCULAR BEHCET'S DISEASE , 2009 .

[9]  H. Gollnick,et al.  Epidemiological features of Adamantiades-Behçet's disease in Germany and in Europe. , 1997, Yonsei medical journal.

[10]  M. Mochizuki Immunotherapy for Behçet's disease. , 1997, International reviews of immunology.

[11]  U. Pleyer,et al.  Therapy of Behçet's disease. , 1996, German journal of ophthalmology.

[12]  H. Goto,et al.  [Incidence of uveitis at Tokyo Medical College Hospital]. , 1995, Nippon Ganka Gakkai zasshi.

[13]  S. Ohno,et al.  FK506 treatment of noninfectious uveitis. , 1994, American journal of ophthalmology.

[14]  S. Kotake,et al.  [Low dose cyclosporin treatment for ocular lesions of Behçet's disease]. , 1992, Nippon Ganka Gakkai zasshi.

[15]  Calvin G. Barnes,et al.  A controlled trial of azathioprine in Behçet's syndrome. , 1990, The New England journal of medicine.

[16]  K. Masuda,et al.  DOUBLE-MASKED TRIAL OF CYCLOSPORIN VERSUS COLCHICINE AND LONG-TERM OPEN STUDY OF CYCLOSPORIN IN BEHÇET'S DISEASE , 1989, The Lancet.

[17]  D. Benezra,et al.  Treatment and visual prognosis in Behçet's disease. , 1986, The British journal of ophthalmology.

[18]  R. Nussenblatt,et al.  TREATMENT OF INTRAOCULAR INFLAMMATORY DISEASE WITH CYCLOSPORIN A , 1983, The Lancet.

[19]  H. Yazıcı,et al.  A double blind study of colchicine in Behçet's disease. , 1980, Haematologica.

[20]  M. Mochizuki,et al.  The eighth Frederick H. Verhoeff Lecture. presented by saiichi mishima, MD Behçet's disease in Japan: ophthalmologic aspects. , 1979, Transactions of the American Ophthalmological Society.

[21]  K. Masuda,et al.  Visual prognosis in Behcet′s disease: Effects of cyclophosphamide and colchicine , 1978 .

[22]  J. Mamo Treatment of Behcet disease with chlorambucil. A follow-up report. , 1976, Archives of ophthalmology.

[23]  J. Oosterhuis,et al.  Treatment of Behcet's disease with chlorambucil. , 1975, Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde.

[24]  S. Oniki [Pathogenesis and treatment of Behcet's disease]. , 1974, Nippon Ganka Gakkai zasshi.

[25]  W. K. Slack,et al.  HYPERBARIC OXYGENATION CHRONIC OSTEOMYELITIS. , 1965, Lancet.